title: Heterogeneity of neuronal nicotinic acetylcholine receptors in 5-HT-containing chemoreceptor cells of the chicken aorta.
abstract: The effects of nicotinic agonists and antagonists on whole-cell currents and 5-hydroxytryptamine (5-HT) release were studied in order to characterize nicotinic ACh receptors on the 5-HT-containing chemoreceptor cells of the chicken aorta. ACh, nicotine and dimethylphenylpiperazinium (DMPP) evoked concentration-dependent inward currents accompanied by increases in current noise at a holding potential of -70 mV. The peak amplitude of the current response to DMPP was 50% larger than that to either nicotine or ACH: Hexamethonium, alpha - bungarotoxin (alpha - BTX) and methyllycaconitine decreased nicotine-induced inward currents in a concentration-dependent manner. Although hexamethonium (0.1 mM) abolished the current response to nicotine (30 microM), a high concentration (1 microM) of alpha - BTX decreased it only by about 30% of the control response. Methyllycaconitine (0.1 microM) decreased the current response to nicotine to the same extent as did alpha - BTX whilst a high concentration (10 microM) abolished the response. ACh, nicotine and DMPP caused concentration-dependent increases in 5-HT output from the thoracic aorta which effect was blocked by hexamethonium (0.1 mM). Pre-treatment with alpha - BTX (1 microM) for 30 min reduced the output of 5-HT induced by ACh to 70% of the control response. It is suggested that neuronal nicotinic ACh receptors, sensitive and insensitive to alpha - BTX, are present on the chemoreceptor cells of the chicken aorta, the activation of which causes the release of 5-HT.
authors: Laboratory of Pharmacology, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan. sito@vetmed.hokudai.ac.jp
authors: S
authors: S
authors: Ito
authors: T
authors: T
authors: Ohta
authors: Y
authors: Y
authors: Kasai
authors: K
authors: K
authors: Yonekubo
authors: Y
authors: Y
authors: Nakazato
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000157:Aconitine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000465:Algorithms; D000818:Animals; D001013:Aorta, Thoracic / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D002038:Bungarotoxins / Q000494:pharmacology; D002628:Chemoreceptor Cells / Q000187:drug effects / Q000378:metabolism*; D002645:Chickens / Q000502:physiology*; D004246:Dimethylphenylpiperazinium Iodide / Q000494:pharmacology; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D018738:Hexamethonium / Q000494:pharmacology; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D009538:Nicotine / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000494:pharmacology; D018733:Nicotinic Antagonists / Q000494:pharmacology; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism*
chemical_list: D002038:Bungarotoxins; D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D011978:Receptors, Nicotinic; C054634:methyllycaconitine; D012701:Serotonin; D018738:Hexamethonium; D004246:Dimethylphenylpiperazinium Iodide; D009538:Nicotine; D000109:Acetylcholine; D000157:Aconitine